AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01088035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Patients will receive daily carboplatin as a radiation sensitizer prior to radiation each day.
Study NCT03439150 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Absolute flow and resistance measurement
Description: Absolute flow and resistance measurements immediately after PPCI of the culprit vessel (in a STEMI setting) and repeated absolute flow and resistance measurements after 3-7 days
Study NCT00993746 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine plus lidocaine
Description: Bupivacaine 20 ml plus lidocaine 10 ml
Study NCT00993746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine 30 ml
Description: Bupivacaine 30 ml for ultrasound guided infraclavicular brachial plexus block
Study NCT01031446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given through a vein in the arm 1 time a week for 3 weeks, then a one week break and then begin the process again.
Study NCT01031446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: Taken daily by mouth.
Study NCT01031446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given through a vein in the arm 1 time a week for 3 weeks, then a one week break and then begin the process again.
Study NCT01031446 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Blood collection
Study NCT02037659 — intervention group
Intervention type: PROCEDURE
Intervention: DermaBond treatment of Gastric Varices
Description: Endoscopic Ultrasound (EUS) administration of DermaBond glue to control bleeding gastric varices.
Study NCT01845038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTX-TPa ~4µg/day over 2 mos. with natural tears drops
Description: OTX-TPa is a hydrogel punctum plug eluting travoprost in a sustained release of \~4µg/day over 2 months. Subjects in this arm will also receive natural tears drops.
Study NCT01845038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTX-TPb ~3µg/day over 3 months with natural tears drops
Description: OTX-TPb is a hydrogel punctum plug eluting travoprost in a sustained release of \~3µg/day over 3 months. Subjects in this arm will also receive natural tears drops.
Study NCT01845038 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Timolol Maleate (0.5%) dosed twice daily with punctum plug without drug
Description: Timolol Maleate (0.5%) ophthalmic solution dosed twice daily. Subjects in this arm will also have a hydrogel punctum plug without drug placed.
Study NCT05932550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc 300 mg
Description: 10 week treatment as add-on therapy to anti-depressants
Study NCT01476787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 on days 1, 8, 15 and 22 of cycle 1, day 1 of cycles 2 to 6; 8 weeks later responding patients continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles.
Study NCT01476787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 20-mg on days 2-22 every 28 days x 6 cycles, if CR then 10-mg on days 2-22 every 28 days for 12 cycles. PR after 6 cycles, continue 20 mg for 3\~6 cycles and then 10 mg on days 2-22 every 28-day cycles for upto 18 cycles
Study NCT01476787 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab-CHOP
Description: 7 to 8 weeks later responding patients will continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles.
Study NCT01476787 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab-CVP
Description: 7 to 8 weeks later responding patients will continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles.
Study NCT01476787 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab-Bendamustine
Description: 7 to 8 weeks later responding patients will continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles.
Study NCT02403609 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BPT, Computerized Assessment
Study NCT02544932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dabigatran
Description: After randomization, patients of this group was will be treated to dabigatran 110mg or 150mg twice a day for 24months
Study NCT02544932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribaroxaban
Description: After randomization, patients of this group was will be treated to ribaroxaban 20mg once a day for 24months.
Study NCT02544932 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: After randomization, patients of this group was will be treated to warfarin and controlled by INR 2-3 for 24months.
Study NCT02542709 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active repetitive Transcranial Magnetic Stimulation
Description: Active transcranial magnetic stimulation will induce real pulses using the transcranial magnetic stimulation device.
Study NCT02542709 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham repetitive Transcranial Magnetic Stimulation
Description: Sham transcranial magnetic stimulation will not induce any pulses using the same transcranial magnetic stimulation device but by also adding a sham block device.
Study NCT04797832 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV Sodium Ferric Gluconate Complex
Description: 125 mg of IV Iron per day to 3 to 5 days according to hospitalisation length.
Study NCT02901288 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoniazid
Description: Isoniazid is a widely used anti-tuberculosis medication. Its primary action is to inhibit the synthesis of long-chain mycolic acids, which are unique components of mycobacterial cell wall.
Study NCT02901288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid
Description: Isoniazid is a widely used anti-tuberculosis medication. Its primary action is to inhibit the synthesis of long-chain mycolic acids, which are unique components of mycobacterial cell wall.
Study NCT02901288 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifampicin
Description: Rifampicin is a widely used anti-tuberculosis medication.
Study NCT02901288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: Rifampicin is a widely used anti-tuberculosis medication.
Study NCT02901288 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pyrazinamide
Description: Pyrazinamide is a commonly used medication for tuberculosis, with bactericidal effect against intracellular mycobacterium tuberculosis.
Study NCT02901288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrazinamide
Description: Pyrazinamide is a commonly used medication for tuberculosis, with bactericidal effect against intracellular mycobacterium tuberculosis.
Study NCT02901288 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ethambutol
Description: Ethambutol is a widely used medicine in anti-TB regimens with bacteriostatic effect against M. tb.
Study NCT02901288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethambutol
Description: Ethambutol is a widely used medicine in anti-TB regimens with bacteriostatic effect against M. tb.
Study NCT02901288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Description: Levofloxacin is a commonly used antimicrobial for TB and other infections, which acts on the DNA-DNA-gyrase complex and topoisomerase IV. It is the S (-) enantiomer of the racemic active substance ofloxacin.
Study NCT00692211 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mailed fecal occult blood tests
Description: Stool blood test
Study NCT00692211 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mailed fecal immunochemical tests
Description: Stool blood test
Study NCT02135887 — intervention group
Intervention type: DRUG
Intervention: MB-6
Description: 6# TID with meal
Study NCT02135887 — intervention group
Intervention type: DRUG
Intervention: Placebo
Description: 6# TID with meal
Study NCT01547325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NanoDOX 1% doxycycline monohydrate Hydrogel
Description: 1% doxycycline monohydrate hydrogel
Study NCT01547325 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo hydrogel
Description: placebo hydrogel
Study NCT01317342 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hypothermic oxygenated perfusion (HOPE)
Description: Application of HOPE for 1 hour, perfusion rate 150-300 ml/min, pressure controlled, perfusion pressure \< 3 mm Hg, perfusion route portal vein, recirculating system, perfusion volume 2 L, perfusate Institute George Lopez solution (IGL-1), perfusate temperature 4-6 °C, perfusate oxygenation 150-200 mm Hg
Study NCT05280678 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Orthodontic miniscrew insertion in the mandibular buccal shelf
Description: Each patient received miniscrews in both sizes. The same orthodontist (M.S.) performed all the insertion procedures. Miniscrews were always placed in the mandibular buccal shelf, laterally to the first and second molar interproximal area, with angulation 30 degree to the bone surface, meaning that miniscrew angulation should be approximately the same as the axial inclination of the adjacent molar. Miniscrews were loaded with orthodontic force 2 weeks after the surgery. The investigated factors were:~* long-term success rate of the miniscrews in the buccal shelf of the mandible (miniscrews were considered long-term stable if they served as an anchorage until completion of mandibular distalization, at least 9 months);~* peri-implantitis development (enlargement of the gingiva and/or redness and/or tendency to bleed);~* the patient's report of pain lasting longer than 48 hours after miniscrew insertion.
Study NCT02708953 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracic manipulation (Manipulation Group)
Description: Manipulation techniques will include: CT junction manipulation seated and supine, upper thoracic manipulation, middle thoracic spine manipulation in seated and supine, middle thoracic spine manipulation in prone, thoracic active range of motion exercise and instruction to maintain usual activity level within the limits of pain.
Study NCT02708953 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic Manipulation (Control wait-list)
Description: Manipulation techniques will include: CT junction manipulation seated and supine, upper thoracic manipulation, middle thoracic spine manipulation in seated and supine, middle thoracic spine manipulation in prone, thoracic active range of motion exercise and instruction to maintain usual activity level within the limits of pain.
Study NCT04124146 — intervention group
Intervention type: RADIATION
Intervention: MRI for some patients according functionnal tests results
Description: Depending on the results obtained on the evaluation criteria, additional examinations could be prescribed (imaging) for subjects with an unsatisfactory functional score. There is therefore a potential change in the usual care.
Study NCT06081556 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ultrasonic testing
Description: mean gestational sac diameter（mGSD）, crown-rump length （CRL）, mGSD-CRL, D-dimer (DD), adenosine diphosphate (ADP), arachidonic acid (AA), and the ratio of uterine artery peak systolic value to end-diastolic value (UtA-S/D) were collected
Study NCT02416284 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NFBDG
Description: Intervention consists of:~Lecture presenting the NFBDG, Printed booklet containing the NFBDG, Suggested meal plan for a week, Recipes, Access to a restricted website with further information on the NFBDG, A Facebook-group where Vegetable of the day was presented with a suggested recipe, text-messages with encouragement to follow the guidelines, follow-up phone-calls, common exercise sessions, Free common meals (1 breakfast, 2 lunches, 1 dinner), Free foods (low-fat dairy products, a juice containing grapes, blueberries, chokeberries, and cherries and fruits)
Study NCT01469858 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Siemens magnetom avanto1.5 Tesla, Siemens magnetom trio A Tim system 3 Tesla
Description: functional magnetic resonance imaging
Study NCT00480610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus ointment
Description: Topical application
Study NCT00480610 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo ointment
Description: Topical application
Study NCT04477681 — intervention group
Intervention type: OTHER
Intervention: Data collection
Description: In particular, the patient's demographic data, medical history, previous and concomitant treatments, data on the treatment of interest (legal framework, compassionate use/ off-label), dosage, start date, etc.), clinical data will be collected. biological (including molecular profiling of the tumor if available) and radiological follow-up, information on adverse effects. The data to be filled in is that of the CERFA pharmacovigilance form of the ANSM, but additional fields can be created if necessary.
Study NCT01683201 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Functional exercise class
Description: Functional exercise class running twice weekly for six weeks from week 12 to week 18
Study NCT01683201 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: usual care group
Description: Usual care group adhere to post operative instructions given on discharge from hospital
Study NCT04220996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine
Description: Vortioxetine 10 and 20 mg/day, tablets, orally Patients will receive 10 mg vortioxetine once daily for the first week. At Visit 2, the dose will be increased to 20 mg/day. The dose may subsequently be adjusted to 10 or 20 mg/day at scheduled or unscheduled visits depending on patient's response as per investigator judgment.
Study NCT02652897 — intervention group
Intervention type: PROCEDURE
Intervention: Exposure to glioma resection surgery
Description: The following blood samples will be drawn for hemostasis evaluation: 1. Conventional clotting tests, 2. Rotational thromboelastometry (ROTEM), including EXTEM and FIBTEM; 3. Platelet function as assessed by PFA-200 for; and 4. Platelet function as assessed by ara-tem, adp-tem and trap-tem. All the analyses will be performed before (within a period 24-h before surgery) and after (within of the following periods: 2 h, 24 h and 48 h after surgery).
Study NCT02652897 — intervention group
Intervention type: PROCEDURE
Intervention: Exposure to colon resection surgery
Description: The following blood samples will be drawn for hemostasis evaluation: 1. Conventional clotting tests, 2. Rotational thromboelastometry (ROTEM), including EXTEM and FIBTEM; 3. Platelet function as assessed by PFA-200 for; and 4. Platelet function as assessed by ara-tem, adp-tem and trap-tem. All the analyses will be performed before (within a period 24-h before surgery) and after (within of the following periods: 2 h, 24 h and 48 h after surgery).
Study NCT03678597 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medium Supplemented with Latrunculin B
Description: A medium with in-house supplementation of Latrunculin B to decrease oocyte degeneration after ICSI and improve the survival rate
Study NCT02766829 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cross leg sitting position
Description: Subjects were set on cross leg sitting position before spinal anesthesia begun.
Study NCT02766829 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional sitting position
Description: Subjects were set on traditional sitting position before spinal anesthesia begun.
Study NCT03739450 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem Solving Training (PST)
Description: The PST intervention consists of six sessions that will follow a structured format based on the PST manual. In these sessions, the interventionist will first provide the TBI-specific education, introduce the participant to the PST steps, then help the care partner generate and select a problem to address first. Interventionist will facilitate the care partner's use of the ABCDEF steps of PST to develop a specific action plan to solve the problem. As problems are attempted or solved, the care partner will learn how to perform the steps on his/her own, thus acquiring self-management problem solving skills that will be applicable to future problems. The final session will include a review and generalization of the PST steps and progress made.
Study NCT03739450 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Participants will receive TBI-specific education alone through a workbook. It consists of educational modules for self-study, common sequelae of TBI, issues encountered by care partners, work and school concerns for those with TBI, and on navigating the rehab system and accessing resources. The modules consist of a brief introduction, key definitions, examples, resources, and a summary. Some chapters also include self-directed activities, such as worksheets or checklists. The investigators will provide a brief orientation to the workbook and include open-ended questions about the participants' need for clarification or questions of the education material. The last session will consist of an open discussion about expected problems that may arise post-discharge.
Study NCT03739450 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Participants will receive TBI-specific education alone through a workbook. It consists of educational modules for self-study, common sequelae of TBI, issues encountered by care partners, work and school concerns for those with TBI, and on navigating the rehab system and accessing resources. The modules consist of a brief introduction, key definitions, examples, resources, and a summary. Some chapters also include self-directed activities, such as worksheets or checklists. The investigators will provide a brief orientation to the workbook and include open-ended questions about the participants' need for clarification or questions of the education material. The last session will consist of an open discussion about expected problems that may arise post-discharge.
Study NCT01495442 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: modified Handihaler DPI
Description: subjects randomized to receive 1 inhaled dose on 2 separate days, each dose delivered 2-3 days apart. The radiolabeled albuterol drug powder will be dispersed from either the DET bead-HandiHaler prototype or via the established HandiHaler device standard with the lactose-albuterol formulation provided to us by the sponsor.
Study NCT01495442 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: standard Handihaler DPI
Description: subjects randomized to receive 1 inhaled dose on 2 separate days, each dose delivered 2-3 days apart. The radiolabeled albuterol drug powder will be dispersed from either the DET bead-HandiHaler prototype or via the established HandiHaler device standard with the lactose-albuterol formulation provided to us by the sponsor.
Study NCT03483480 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: NPWT for Pilonidal Surgery
Description: After excision of pilonidal sinus Non powered-NPWT will be applied to the area
Study NCT03483480 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Excision of Pilonidal sinus with normal dressing
Description: After excision of pilonidal sinus normal dressing will be applied to the area of surgery
Study NCT03354754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LYS228
Description: LYS228 IV infusion every 6 hours
Study NCT03354754 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care therapy
Description: IV infusion of standard of care antibiotics
Study NCT03891589 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional education program
Description: These programs were a process of providing information or knowledge to mother of the children consisting of information on initiation of complementary feeding, variety, and frequency of food, nutrient requirements and diet pattern for children (the amount and types of food), and benefits of Taburia. All this information provided through class-based activities and group discussion by using leaflet and food model conducted by the researchers. Education materials developed based on CFR models from our previous study by applying the LP approach. There was also a demonstration on administering complementary feeding (demo and cooking class) to improve skills of the mother on food from selection, design, handling and preparing, based on requirements of the children. This activity conducted through training once per month for the first four months of the intervention. Components of complementary feeding promoted in this study are based on CFR using LP approach from our previous research.
Study NCT03891589 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Home fortification (Taburia)
Description: Taburia is a multivitamin and mineral fortification to provide sufficient amount of nutrient for optimal growth and development of children aged 6-59 months. Every sachet of Taburia prepared to fulfill minimum nutrient requirements for children aged 6-59 months. Each sachet is one gram in weight and contains vitamin A (417 mcg), B1 (0.5 mg), B2 (0.5 mg), B3 (5.0 mg), B6 (0.5 mg), B12 (1 mcg), D3 (5 mcg), E (6 mg), K (20 mcg), C (30 mcg), folic acid (150 mcg), pantothenic acid (3 mcg), Iodium (50 mcg), Iron (10 mg), Zn (5 mg) and Selenium (20 mcg). One sachet of Taburia given to the subject by adding it to their breakfast and must be finished. The frequency of Taburia consumption per week follows the finding of the LP analysis from the previous study. Taburia intervention complemented by health education related to benefits, administration of Taburia, and its side effects. Compliance will be evaluated directly by the researcher based on empty Taburia sachet and conducted every month.